136 related articles for article (PubMed ID: 2965137)
1. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
Harding I; Garaud JJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
[TBL] [Abstract][Full Text] [Related]
2. Teicoplanin in infections caused by methicillin-resistant staphylococci.
Drabu YJ; Walsh B; Blakemore PH; Mehtar S
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
[TBL] [Abstract][Full Text] [Related]
3. Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity.
Chomarat M; Espinouse D; Flandrois JP
J Antimicrob Chemother; 1991 Apr; 27(4):475-80. PubMed ID: 1830301
[TBL] [Abstract][Full Text] [Related]
4. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity.
Jones RN
J Antimicrob Chemother; 1992 Jun; 29(6):725-7. PubMed ID: 1387134
[No Abstract] [Full Text] [Related]
5. Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides, and molecular epidemiology.
Boisson K; Thouverez M; Talon D; Bertrand X
Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):660-5. PubMed ID: 12373498
[TBL] [Abstract][Full Text] [Related]
6. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
Lang E; Földes M; Marghescu S
Infection; 1991; 19(3):190-4. PubMed ID: 1832418
[TBL] [Abstract][Full Text] [Related]
8. Teicoplanin in the treatment of skin and soft tissue infections.
Turpin PJ; Taylor GP; Logan MN; Wood MJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():117-22. PubMed ID: 2965123
[TBL] [Abstract][Full Text] [Related]
9. Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis.
Yalaz M; Cetin H; Akisu M; Yeniay B; Tunger A; Kultursay N
J Int Med Res; 2004; 32(5):540-8. PubMed ID: 15458287
[TBL] [Abstract][Full Text] [Related]
10. Teicoplanin--domiciliary use in surgical infections.
Rubinstein E
Eur J Surg Suppl; 1992; (567):27-9. PubMed ID: 1381638
[TBL] [Abstract][Full Text] [Related]
11. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
[TBL] [Abstract][Full Text] [Related]
13. Spanish experience with teicoplanin.
Fernández-Guerrero M; Gobernado M; Ariza J; Williams A
Scand J Infect Dis Suppl; 1990; 72():38-44. PubMed ID: 2151066
[TBL] [Abstract][Full Text] [Related]
14. Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.
Bertin M; Muller A; Bertrand X; Cornette C; Thouverez M; Talon D
Eur J Clin Microbiol Infect Dis; 2004 May; 23(5):375-9. PubMed ID: 15112071
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital.
Yamada K; Namikawa H; Fujimoto H; Nakaie K; Takizawa E; Okada Y; Fujita A; Kawaguchi H; Nakamura Y; Abe J; Kaneko Y; Kakeya H
Intern Med; 2017; 56(7):781-785. PubMed ID: 28381743
[TBL] [Abstract][Full Text] [Related]
16. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
de Lalla F; Santoro D; Rinaldi E; Suter F; Cruciani M; Guaglianone MH; Rizzardini G; Pellegata G
J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
[TBL] [Abstract][Full Text] [Related]
17. [Comparative in vitro activity of glycopeptides against coagulase negative staphylococci isolated in pediatric hospital units].
Bourgeois F; Bingen E; Lambert-Zechovsky N
Pathol Biol (Paris); 1992 Jan; 40(1):36-9. PubMed ID: 1533278
[TBL] [Abstract][Full Text] [Related]
18. Red man syndrome with teicoplanin.
Dubettier S; Boibieux A; Lagable M; Crevon L; Peyramond D; Milon H
Rev Infect Dis; 1991; 13(4):770. PubMed ID: 1833809
[No Abstract] [Full Text] [Related]
19. Teicoplanin-resistant coagulase-negative staphylococci.
Brumeitt W; Hamilton-Miller JM; Neville LO
Lancet; 1987 Feb; 1(8528):328. PubMed ID: 2880140
[No Abstract] [Full Text] [Related]
20. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci.
Bourgeois I; Pestel-Caron M; Lemeland JF; Pons JL; Caron F
Antimicrob Agents Chemother; 2007 Feb; 51(2):740-3. PubMed ID: 17116684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
